Coen Stacy Ann

SEC source: 0001641172-25-014931 · ownership.xml · derivative · entry 1

Coen Stacy Ann · CIK 0001814150 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,000

Underlying: Common Stock · 22,000 shares

Expires 2025-06-11

F1 · derivative.exercise_date: The options will vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual meeting.

SEC source: 0001493152-24-034066 · ownership.xml · derivative · entry 1

Coen Stacy Ann · CIK 0001814150 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2034-08-26

F1 · derivative.exercise_date: The options will vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual meeting.

SEC source: 0001104659-24-014711 · tm245865-11_4seq1.xml · derivative · entry 7

Coen Stacy Ann · CIK 0001814150 · SVP & CHIEF BUSINESS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 39,293 shares

Expires not disclosed

F4 · derivative.exercise_price: Pursuant to the Merger Agreement, at the Effective Time, each RSU granted on or after the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was converted into a grant of restricted stock unit awards in respect of a number of shares of AbbVie common stock equal to the number of shares of Common Stock underlying such RSU as of immediately prior to the Effective Time multiplied by 0.18, and otherwise with the same terms and conditions that were applicable immediately prior to the Effective Time.

F4 · kind: Pursuant to the Merger Agreement, at the Effective Time, each RSU granted on or after the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was converted into a grant of restricted stock unit awards in respect of a number of shares of AbbVie common stock equal to the number of shares of Common Stock underlying such RSU as of immediately prior to the Effective Time multiplied by 0.18, and otherwise with the same terms and conditions that were applicable immediately prior to the Effective Time.

F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each RSU granted on or after the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was converted into a grant of restricted stock unit awards in respect of a number of shares of AbbVie common stock equal to the number of shares of Common Stock underlying such RSU as of immediately prior to the Effective Time multiplied by 0.18, and otherwise with the same terms and conditions that were applicable immediately prior to the Effective Time.

F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each RSU granted on or after the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was converted into a grant of restricted stock unit awards in respect of a number of shares of AbbVie common stock equal to the number of shares of Common Stock underlying such RSU as of immediately prior to the Effective Time multiplied by 0.18, and otherwise with the same terms and conditions that were applicable immediately prior to the Effective Time.

F4 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each RSU granted on or after the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was converted into a grant of restricted stock unit awards in respect of a number of shares of AbbVie common stock equal to the number of shares of Common Stock underlying such RSU as of immediately prior to the Effective Time multiplied by 0.18, and otherwise with the same terms and conditions that were applicable immediately prior to the Effective Time.

SEC source: 0001104659-24-014711 · tm245865-11_4seq1.xml · derivative · entry 6

Coen Stacy Ann · CIK 0001814150 · SVP & CHIEF BUSINESS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 28,700 shares

Expires not disclosed

F3 · derivative.exercise_price: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of common stock, par value $.01 per share, of the Issuer ("Common Stock") subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration.

F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of common stock, par value $.01 per share, of the Issuer ("Common Stock") subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration.

F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of common stock, par value $.01 per share, of the Issuer ("Common Stock") subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration.

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of common stock, par value $.01 per share, of the Issuer ("Common Stock") subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration.

F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of common stock, par value $.01 per share, of the Issuer ("Common Stock") subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration.

SEC source: 0001104659-24-014711 · tm245865-11_4seq1.xml · derivative · entry 5

Coen Stacy Ann · CIK 0001814150 · SVP & CHIEF BUSINESS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 65,000 shares

Expires 2030-06-01

F2 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.

F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.

SEC source: 0001104659-24-014711 · tm245865-11_4seq1.xml · derivative · entry 4

Coen Stacy Ann · CIK 0001814150 · SVP & CHIEF BUSINESS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 258,195 shares

Expires 2033-02-03

F2 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.

F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.

SEC source: 0001104659-24-014711 · tm245865-11_4seq1.xml · derivative · entry 3

Coen Stacy Ann · CIK 0001814150 · SVP & CHIEF BUSINESS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 303,465 shares

Expires 2032-02-04

F2 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.

F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.

SEC source: 0001104659-24-014711 · tm245865-11_4seq1.xml · derivative · entry 2

Coen Stacy Ann · CIK 0001814150 · SVP & CHIEF BUSINESS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 150,610 shares

Expires 2031-02-05

F2 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.

F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.

SEC source: 0001104659-24-014711 · tm245865-11_4seq1.xml · nonDerivative · entry 1

Coen Stacy Ann · CIK 0001814150 · SVP & CHIEF BUSINESS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation ("AbbVie"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie ("Intermediate Sub"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub ("Purchaser"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $.01 per share, of the Issuer (the "Common Stock"), that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive an amount in cash equal to $31.26, without interest (the "Merger Consideration").

F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation ("AbbVie"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie ("Intermediate Sub"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub ("Purchaser"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $.01 per share, of the Issuer (the "Common Stock"), that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive an amount in cash equal to $31.26, without interest (the "Merger Consideration").

SEC source: 0001415889-24-002873 · form4-02072024_020202.xml · nonDerivative · entry 2

Coen Stacy Ann · CIK 0001814150 · SVP & CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 73,274

F1 · kind: Effected pursuant to a trading plan adopted on June 15, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

SEC source: 0001415889-24-002873 · form4-02072024_020202.xml · derivative · entry 3

Coen Stacy Ann · CIK 0001814150 · SVP & CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 28,700

Underlying: Common Stock · 14,350 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.

F2 · price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.

F3 · derivative.exercise_date: The RSUs were awarded on 2/3/2023 and vest over a three-year period, with 33 1/3% of the RSUs vesting on each of the first three anniversaries of the date of grant, subject to continued service through each vesting date.

F3 · derivative.expiration_date: The RSUs were awarded on 2/3/2023 and vest over a three-year period, with 33 1/3% of the RSUs vesting on each of the first three anniversaries of the date of grant, subject to continued service through each vesting date.

SEC source: 0001415889-24-002873 · form4-02072024_020202.xml · nonDerivative · entry 1

Coen Stacy Ann · CIK 0001814150 · SVP & CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 77,857

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-24-002761 · form4-02062024_020214.xml · derivative · entry 1

Coen Stacy Ann · CIK 0001814150 · SVP & CHIEF BUSINESS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,293

Underlying: Common Stock · 39,293 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.

F1 · price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.

F2 · derivative.exercise_date: The RSUs vest over a three-year period, with 33 1/3% of the RSUs vesting on each of the first three anniversaries of the date of grant, subject to continued service through each vesting date.

F2 · derivative.expiration_date: The RSUs vest over a three-year period, with 33 1/3% of the RSUs vesting on each of the first three anniversaries of the date of grant, subject to continued service through each vesting date.

SEC source: 0001415889-24-000381 · form4-01032024_100137.xml · derivative · entry 3

Coen Stacy Ann · CIK 0001814150 · SVP & CHIEF BUSINESS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 303,465

Underlying: Common Stock · 30,000 shares

Expires 2032-02-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This option was granted on February 4, 2022 and is exercisable as to 25% on the first year anniversary of the grant and 6.25% quarterly for the subsequent three years.

SEC source: 0001415889-24-000381 · form4-01032024_100137.xml · nonDerivative · entry 2

Coen Stacy Ann · CIK 0001814150 · SVP & CHIEF BUSINESS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,507

F1 · security: These shares were purchased due to participation by the reporting individual in the ImmunoGen Employee Stock Purchase Plan (the ESPP). It pertains to the ESPP purchase period from July 1, 2023 through December 31, 2023.

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on July 3, 2023

SEC source: 0001415889-24-000381 · form4-01032024_100137.xml · nonDerivative · entry 1

Coen Stacy Ann · CIK 0001814150 · SVP & CHIEF BUSINESS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,140

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-23-015909 · form4-12062023_021256.xml · nonDerivative · entry 1

Coen Stacy Ann · CIK 0001814150 · SVP & CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33,140

F1 · kind: Effected pursuant to a trading plan adopted on August 10, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

SEC source: 0001415889-23-015268 · form4-11182023_121148.xml · derivative · entry 15

Coen Stacy Ann · CIK 0001814150 · SVP & CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 76,787

Underlying: Common Stock · 76,023 shares

Expires 2031-02-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Effected pursuant to a trading plan adopted on August 10, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F6 · derivative.exercise_date: This option was granted on February 5, 2021 and is exercisable as to 25% on the first year anniversary of the grant and 6.25% quarterly for the subsequent three years.

SEC source: 0001415889-23-015268 · form4-11182023_121148.xml · derivative · entry 14

Coen Stacy Ann · CIK 0001814150 · SVP & CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 48,823

Underlying: Common Stock · 2,200 shares

Expires 2030-06-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Effected pursuant to a trading plan adopted on August 10, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F5 · derivative.exercise_date: This option was granted on June 1, 2020 and is exercisable as to 25% on the first year anniversary of the grant and 6.25% quarterly for the subsequent three years.

SEC source: 0001415889-23-015268 · form4-11182023_121148.xml · nonDerivative · entry 9

Coen Stacy Ann · CIK 0001814150 · SVP & CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,966

F1 · kind: Effected pursuant to a trading plan adopted on August 10, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.17, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges.

SEC source: 0001415889-23-015268 · form4-11182023_121148.xml · nonDerivative · entry 8

Coen Stacy Ann · CIK 0001814150 · SVP & CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 115,189

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Effected pursuant to a trading plan adopted on August 10, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

SEC source: 0001415889-23-015268 · form4-11182023_121148.xml · nonDerivative · entry 7

Coen Stacy Ann · CIK 0001814150 · SVP & CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 39,166

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Effected pursuant to a trading plan adopted on August 10, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

SEC source: 0001415889-23-015268 · form4-11182023_121148.xml · derivative · entry 13

Coen Stacy Ann · CIK 0001814150 · SVP & CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 152,810

Underlying: Common Stock · 900 shares

Expires 2031-02-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Effected pursuant to a trading plan adopted on August 10, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F6 · derivative.exercise_date: This option was granted on February 5, 2021 and is exercisable as to 25% on the first year anniversary of the grant and 6.25% quarterly for the subsequent three years.

SEC source: 0001415889-23-015268 · form4-11182023_121148.xml · derivative · entry 12

Coen Stacy Ann · CIK 0001814150 · SVP & CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 51,023

Underlying: Common Stock · 3,200 shares

Expires 2030-06-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Effected pursuant to a trading plan adopted on August 10, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F5 · derivative.exercise_date: This option was granted on June 1, 2020 and is exercisable as to 25% on the first year anniversary of the grant and 6.25% quarterly for the subsequent three years.

SEC source: 0001415889-23-015268 · form4-11182023_121148.xml · nonDerivative · entry 6

Coen Stacy Ann · CIK 0001814150 · SVP & CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,966

F1 · kind: Effected pursuant to a trading plan adopted on August 10, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.02, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges.

SEC source: 0001415889-23-015268 · form4-11182023_121148.xml · nonDerivative · entry 5

Coen Stacy Ann · CIK 0001814150 · SVP & CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 41,066

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Effected pursuant to a trading plan adopted on August 10, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

SEC source: 0001415889-23-015268 · form4-11182023_121148.xml · nonDerivative · entry 4

Coen Stacy Ann · CIK 0001814150 · SVP & CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 40,166

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Effected pursuant to a trading plan adopted on August 10, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

SEC source: 0001415889-23-015268 · form4-11182023_121148.xml · derivative · entry 11

Coen Stacy Ann · CIK 0001814150 · SVP & CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 153,710

Underlying: Common Stock · 5,300 shares

Expires 2031-02-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Effected pursuant to a trading plan adopted on August 10, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F6 · derivative.exercise_date: This option was granted on February 5, 2021 and is exercisable as to 25% on the first year anniversary of the grant and 6.25% quarterly for the subsequent three years.

SEC source: 0001415889-23-015268 · form4-11182023_121148.xml · derivative · entry 10

Coen Stacy Ann · CIK 0001814150 · SVP & CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 54,223

Underlying: Common Stock · 20,986 shares

Expires 2030-06-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Effected pursuant to a trading plan adopted on August 10, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F5 · derivative.exercise_date: This option was granted on June 1, 2020 and is exercisable as to 25% on the first year anniversary of the grant and 6.25% quarterly for the subsequent three years.

SEC source: 0001415889-23-015268 · form4-11182023_121148.xml · nonDerivative · entry 3

Coen Stacy Ann · CIK 0001814150 · SVP & CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,966

F1 · kind: Effected pursuant to a trading plan adopted on August 10, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.03, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges.

SEC source: 0001415889-23-015268 · form4-11182023_121148.xml · nonDerivative · entry 2

Coen Stacy Ann · CIK 0001814150 · SVP & CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 63,252

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Effected pursuant to a trading plan adopted on August 10, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

SEC source: 0001415889-23-015268 · form4-11182023_121148.xml · nonDerivative · entry 1

Coen Stacy Ann · CIK 0001814150 · SVP & CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 57,952

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Effected pursuant to a trading plan adopted on August 10, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

SEC source: 0001415889-23-013144 · form4-09112023_080942.xml · derivative · entry 2

Coen Stacy Ann · CIK 0001814150 · SVP & CHIEF BUSINESS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 159,010

Underlying: Common Stock · 26,006 shares

Expires 2031-02-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Exercisable as to 25% on the first year anniversary of the grant and 6.25% quarterly for the subsequent three years.

SEC source: 0001415889-23-013144 · form4-09112023_080942.xml · nonDerivative · entry 1

Coen Stacy Ann · CIK 0001814150 · SVP & CHIEF BUSINESS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,966

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-23-012146 · form4-08112023_090823.xml · derivative · entry 3

Coen Stacy Ann · CIK 0001814150 · SVP & CHIEF BUSINESS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,209

Underlying: Common Stock · 100,210 shares

Expires 2030-06-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Exercisable as to 25% on the first year anniversary of the grant and 6.25% quarterly for the subsequent three years.

SEC source: 0001415889-23-012146 · form4-08112023_090823.xml · nonDerivative · entry 2

Coen Stacy Ann · CIK 0001814150 · SVP & CHIEF BUSINESS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,960

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.97 to $14.46, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges.

SEC source: 0001415889-23-012146 · form4-08112023_090823.xml · nonDerivative · entry 1

Coen Stacy Ann · CIK 0001814150 · SVP & CHIEF BUSINESS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 111,170

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-23-011882 · form4-08042023_110803.xml · derivative · entry 6

Coen Stacy Ann · CIK 0001814150 · SVP & CHIEF BUSINESS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 175,419

Underlying: Common Stock · 80,326 shares

Expires 2030-06-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Exercisable as to 25% on the first year anniversary of the grant and 6.25% quarterly for the subsequent three years.

SEC source: 0001415889-23-011882 · form4-08042023_110803.xml · nonDerivative · entry 4

Coen Stacy Ann · CIK 0001814150 · SVP & CHIEF BUSINESS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,960

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.00 to $17.12, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges.

SEC source: 0001415889-23-011882 · form4-08042023_110803.xml · nonDerivative · entry 3

Coen Stacy Ann · CIK 0001814150 · SVP & CHIEF BUSINESS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 91,286

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-23-011882 · form4-08042023_110803.xml · derivative · entry 5

Coen Stacy Ann · CIK 0001814150 · SVP & CHIEF BUSINESS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 255,745

Underlying: Common Stock · 4,255 shares

Expires 2030-06-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Exercisable as to 25% on the first year anniversary of the grant and 6.25% quarterly for the subsequent three years.

SEC source: 0001415889-23-011882 · form4-08042023_110803.xml · nonDerivative · entry 2

Coen Stacy Ann · CIK 0001814150 · SVP & CHIEF BUSINESS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,960

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.01 to $18.15, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges.

SEC source: 0001415889-23-011882 · form4-08042023_110803.xml · nonDerivative · entry 1

Coen Stacy Ann · CIK 0001814150 · SVP & CHIEF BUSINESS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,215

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-23-010825 · form4-07052023_090749.xml · nonDerivative · entry 1

Coen Stacy Ann · CIK 0001814150 · SVP & CHIEF BUSINESS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,960

F1 · security: These shares were purchased due to participation by the reporting individual in the ImmunoGen Employee Stock Purchase Plan (the ESPP). It pertains to the ESPP purchase period from January 1, 2023 through June 30, 2023.

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on January 3, 2023.

SEC source: 0001415889-23-002105 · form4-02072023_100207.xml · derivative · entry 2

Coen Stacy Ann · CIK 0001814150 · SVP & CHIEF BUSINESS OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 245,900

Underlying: Common Stock · 245,900 shares

Expires 2033-02-03

F3 · derivative.exercise_date: These options vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the date of grant, and thereafter an additional 6.25% of the shares vesting on each succeeding quarterly anniversary of the date of grant.

SEC source: 0001415889-23-002105 · form4-02072023_100207.xml · derivative · entry 1

Coen Stacy Ann · CIK 0001814150 · SVP & CHIEF BUSINESS OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,000

Underlying: Common Stock · 41,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.

F1 · price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.

F2 · derivative.exercise_date: The RSUs vest over a three-year period, with 33 1/3% of the RSUs vesting on each of the first three anniversaries of the date of grant, subject to continued service through each vesting date.

F2 · derivative.expiration_date: The RSUs vest over a three-year period, with 33 1/3% of the RSUs vesting on each of the first three anniversaries of the date of grant, subject to continued service through each vesting date.

SEC source: 0001415889-22-012996 · form4-12272022_101257.xml · derivative · entry 2

Coen Stacy Ann · CIK 0001814150 · SVP & CHIEF BUSINESS OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Common Stock · 60,000 shares

Expires 2030-06-01

F2 · derivative.exercise_date: On June 1, 2020, the reporting person was granted an option to purchase 120,000 shares of common stock. The option vests in installments upon the satisfaction of certain performance criteria. On November 14, 2022, certain performance criteria were met, resulting in the vesting of 50% of the performance stock option award.

SEC source: 0001415889-22-007337 · form4-07052022_010742.xml · nonDerivative · entry 1

Coen Stacy Ann · CIK 0001814150 · SVP & CHIEF BUSINESS OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,168

F1 · security: These shares were purchased due to participation by the reporting individual in the ImmunoGen Employee Stock Purchase Plan (the ESPP). It pertains to the ESPP purchase period from January 1, 2022 through June 30, 2022

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on June 30, 2022

SEC source: 0001415889-22-012996 · form4-12272022_101257.xml · derivative · entry 1

Coen Stacy Ann · CIK 0001814150 · SVP & CHIEF BUSINESS OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2030-06-01

F1 · derivative.exercise_date: On June 1, 2020, the reporting person was granted an option to purchase 120,000 shares of common stock. The option vests in installments upon the satisfaction of certain performance criteria. On May 20, 2022, certain performance criteria were met, resulting in the vesting of 25% of the performance stock option award.

SEC source: 0001179110-22-000925 · edgar.xml · derivative · entry 1

Coen Stacy Ann · CIK 0001814150 · SVP & Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 333,465

Underlying: Common Stock · 333,465 shares

Expires 2032-02-04

F1 · derivative.exercise_date: These options vest over a four-year period, with 25% of the shares vesting on the one year anniversary of the date of grant, and thereafter an additional 6.25% of the shares vesting on each succeeding quarterly anniversary of the date of grant.